Black Diamond Therapeutics (BDTX) Expected to Announce Quarterly Earnings on Thursday

Black Diamond Therapeutics (NASDAQ:BDTX) is anticipated to release its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect Black Diamond Therapeutics to post earnings of ($0.18) per share for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 6, 2026 at 4:00 PM ET.

Black Diamond Therapeutics Stock Performance

Shares of BDTX opened at $2.59 on Thursday. Black Diamond Therapeutics has a fifty-two week low of $1.20 and a fifty-two week high of $4.94. The business has a 50-day moving average of $2.50 and a 200 day moving average of $3.10. The firm has a market cap of $147.55 million, a P/E ratio of 7.19 and a beta of 3.36.

Wall Street Analyst Weigh In

BDTX has been the topic of several research reports. Zacks Research lowered shares of Black Diamond Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Black Diamond Therapeutics in a report on Monday, December 29th. Piper Sandler lowered their target price on shares of Black Diamond Therapeutics from $9.00 to $8.00 and set an “overweight” rating on the stock in a report on Friday, January 16th. Finally, Guggenheim downgraded Black Diamond Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 3rd. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $9.33.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Invesco Ltd. boosted its stake in shares of Black Diamond Therapeutics by 30.9% in the 2nd quarter. Invesco Ltd. now owns 60,210 shares of the company’s stock valued at $149,000 after purchasing an additional 14,221 shares in the last quarter. AQR Capital Management LLC bought a new stake in Black Diamond Therapeutics in the first quarter worth $84,000. Engineers Gate Manager LP grew its stake in shares of Black Diamond Therapeutics by 48.9% during the fourth quarter. Engineers Gate Manager LP now owns 19,701 shares of the company’s stock valued at $48,000 after buying an additional 6,469 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Black Diamond Therapeutics in the third quarter worth about $39,000. Finally, Prudential Financial Inc. bought a new stake in shares of Black Diamond Therapeutics in the 2nd quarter valued at about $32,000. 95.47% of the stock is currently owned by hedge funds and other institutional investors.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc is a precision oncology company focused on the discovery and development of small-molecule therapies that selectively target oncogenic proteins bearing tumor-driving mutations. Leveraging its proprietary Genetic Defined Allosteric (GDA) therapeutic platform, the company aims to identify unique allosteric binding sites in mutant proteins and engineer highly selective inhibitors. Headquartered in Cambridge, Massachusetts, Black Diamond applies structure-based drug design and molecular modeling to advance personalized cancer treatments.

The company’s development pipeline includes lead candidate BDTX-189, an allosteric inhibitor of mutant HER2, as well as programs directed at clinically relevant EGFR and KRAS mutations.